[2] Compl., Eli Lilly and Co
Just stick to recommended servings and choose high-quality products
Serious Adverse Events Serious adverse events are uncommon but include acute pancreatitis (incidence similar to other GLP-1 agonists, approximately 0.2%), gallbladder disorders (cholecystitis, cholelithiasis) occurring more frequently than placebo likely due to rapid weight loss, and rare cases of severe hypoglycemia when combined with insulin or sulfonylureas
Preclinical research suggests GLP-1 receptor activation may reduce neuroinflammation, decrease amyloid-beta accumulation, enhance synaptic plasticity, and improve brain glucose metabolism
The degree of HbA1c reduction and weight reduction observed in Phase 3 clinical trials is unprecedented
Their rise has been nothing short of meteoric